Marc Voigt
Chief Executive Officer bei IMMUTEP LIMITED
Vermögen: 3 Mio $ am 31.03.2024
Profil
Marc Voigt is currently the Chief Executive Officer & Executive Director at Immutep Ltd.
He is also the Chairman-Supervisory Board & President at Immutep SAS.
Additionally, he serves as the Co-Managing Director at Immutep GmbH and as a Member at Pharma-Lizenz-Club Deutschland.
In his former positions, Mr. Voigt was the Vice Chairman-Supervisory Board at Elanix Biotechnologies AG.
He also held the position of Director-Finance, Legal & Business Development at Medical Enzymes AG from 1998 to 2012.
During his time at Allianz SE, he worked as a Principal from 2001 to 2009.
Mr. Voigt was the Chief Financial Officer at Revotar Biopharmaceuticals AG from 2003 to 2006.
He also worked as a Principal at Allianz Versicherungs AG and as the MD, Chief Operating & Financial Officer at caprotec bioanalytics GmbH.
Additionally, he served as the General Manager-European Operations at Immutep GmbH.
Mr. Voigt obtained an MBA from Freie Universität Berlin.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMUTEP LTD
0,94% | 22.08.2023 | 11 191 695 ( 0,94% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Marc Voigt
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUTEP LIMITED | Chief Executive Officer | 09.07.2014 |
| Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Immutep SAS
 Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Chairman | 18.11.2015 |
Immutep GmbH
 Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The private company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Marc Voigt
| Unternehmen | Position | Ende |
|---|---|---|
Medical Enzymes AG
 Medical Enzymes AG Medical/Nursing ServicesHealth Services Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG. Medical Enzymes business strategy focuses on the clinical development of therapeutic enzymes until clinical proof of concept and to commercialize those products through collaboration with selected pharmaceutical partners. | Director of Finance/CFO | 02.01.2006 |
Revotar Biopharmaceuticals AG
 Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany. | Director of Finance/CFO | 02.01.2006 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The private company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | Corporate Officer/Principal | - |
| ELANIX BIOTECHNOLOGIES AG | Director/Board Member | - |
caprotec bioanalytics GmbH
 caprotec bioanalytics GmbH BiotechnologyHealth Technology caprotec bioanalytics GmbH commercializes Capture Compound Mass Spectrometry technology. It offers compound profiling services, supplies managing risk services, support the development of the health market and biomarker, rescues projects, selects and optimizes the development processes, and offers collaborations with other companies. The company was founded by Hubert Koester in 2007 and is headquartered in Berlin, Germany. | Director of Finance/CFO | - |
Ausbildung von Marc Voigt
| Freie Universität Berlin | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ALLIANZ SE | Finance |
| IMMUTEP LIMITED | Health Technology |
| ELANIX BIOTECHNOLOGIES AG | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany. | Health Technology |
Allianz Versicherungs AG
 Allianz Versicherungs AG Multi-Line InsuranceFinance Allianz Versicherungs-AG engages in the non-life insurance business. It provides general accident, liability, vehicle, legal expense, fire, credit and surety, as well as transport insurance services. The company is headquartered in Munich, Germany. | Finance |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology caprotec bioanalytics GmbH commercializes Capture Compound Mass Spectrometry technology. It offers compound profiling services, supplies managing risk services, support the development of the health market and biomarker, rescues projects, selects and optimizes the development processes, and offers collaborations with other companies. The company was founded by Hubert Koester in 2007 and is headquartered in Berlin, Germany. | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG. Medical Enzymes business strategy focuses on the clinical development of therapeutic enzymes until clinical proof of concept and to commercialize those products through collaboration with selected pharmaceutical partners. | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Health Technology |
| Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The private company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | Health Technology |
